ANALYTICAL AND LABORATORY EQUIPMENT 9 SECTION NAME 2
interoperable across browsers on multiple devices.
Researchers across all domains can enjoy greater freedom to access and input data, increasing collaboration and the sharing of intellectual property (IP) across the enterprise.
“Today’s labs are asking for so much more and we’re aligning our software with where the science is taking our customers. We’ve invested significant R&D into E WorkBook 10 to deliver major enhancements to our proven technology. It means researchers can spend less time finding things and more time doing science with advanced data insight,” explained Scott Weiss, director of product strategy at IDBS.
Weiss highlights the five key features of E-WorkBook 10: new ways to visualise and use data, including enhanced charting and canvasing capabilities; simple, intuitive interface for faster working; flexible data access via internet browsers with a web connection; spreadsheet functionality available via the web browser; and a foundation for future industry demands.
Cross-domain platform Te attraction of E-WorkBook solutions is highlighted by the
W
decision of Boehringer Ingelheim to use it to eliminate data silos in the lab.
Te cross-domain platform has initially been deployed in North America with the next roll-out planned for Germany.
Users are benefiting from streamlined R&D with increases in data quality and productivity. Boehringer Ingelheim scientists can now easily and simply capture and record data electronically. Information is both searchable and retrievable for better data sharing and efficiency.
Multiple systems are being consolidated for a centralised and highly configurable data flow.
Over the next few years, the system is planned to be rolled out to up to 2,400 users globally.
Te company will also look to integrate E-WorkBook with existing lab infrastructure as well as external LIMS, SAP and data management systems.
For its part GenomeDx Biosciences has implemented GenoLogics’ laboratory information management system (LIMS), Clarity LIMS, to support whole transcriptome analysis workflows as part of its mission to address unmet clinical
needs in the management of prostate cancer.
In the USA alone, there are an estimated 2.5 million men who are living with prostate cancer. An estimated 230,000 are diagnosed each year with over 100,000 undergoing surgery to treat their cancer.
According to clinical risk assessment, nearly half of men should be considered for post- surgery radiation even though their cancer may not recur.
Using its novel genomic test, the Decipher prostate cancer classifier, GenomeDx is able to predict the probability of cancer spread for men after surgery.
Clinicians can then use this information, along with other clinical factors, to better guide postoperative treatment decisions and in certain men, avoid the side effects and high costs associated with treatment.
Cloud-based LIMS GenomeDx will use the cloud- based version of Clarity LIMS to support samples processed using the Decipher test. Built specifically for genomics labs, Clarity LIMS provides end-to-end sample tracking, automation, preconfigured workflows, and excellent usability.
China establishes national technical support centre for standardisation and screening
aters Corporation has announced the inauguration of its Joint Open Laboratory established together with the Chinese
Pharmacopeia Commission (ChP). It will be jointly operated by both organisations. The ChP is an official and authoritative
compendium of drugs and has been in place since 1950, publishing compendiums in 1953, 1963, 1977, 1985, 1990, 1995, 2000, 2005, and 2010. Formerly reporting under the Chinese Ministry of
Health, it is now is an affiliated commission of the newly formed Chinese Food and Drug Administration (CFDA). In addition, The Chinese Pharmacopeia
Commission is also officially recognised by the World Health Organisation. Focus areas for the new laboratory include in-depth
research of pharmacopoeia standards, development of testing methods, methods validations and basic and advanced technical training of pharmacopoeia detection methods. The laboratory is also anticipated to play a role as
one of the national technical support centres in the field of Chinese pharmaceutical standards. Speaking at the inauguration ceremony, Mike
Harrington, vice president of Waters Asia Pacific and European operations, noted: “Our co-operation with
ChP to open and operate this cooperative laboratory in China reflects our commitment to consistently push the boundaries of what’s possible by helping to bring more resources to bear that enable innovations in China’s pharmaceutical and biopharma industries.” “Our co-operation will meet the needs of ChP’s
development, while also responding to the demands of even further enhancements to pharmacopoeia standards and improved public drug safety,” said Secretary General Zhang Wei of the ChP. The joint open lab is located within the laboratory building of the Beijing Zhendong Guangming Drug Research Institute.
www.scientistlive.com
“Our latest
solution enables researchers to spend less time finding things and more time doing science with advanced data insight.”
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92